# Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT

> **NCT06963866** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xuzhou Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Myeloma, Newly Diagnosed

## Interventions

- **BIOLOGICAL:** autologous stem cell transplantation
- **BIOLOGICAL:** CAR-T

## Key facts

- **NCT ID:** NCT06963866
- **Lead sponsor:** Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06963866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06963866, "Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06963866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*